These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 21245100

  • 1. Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.
    Sabnis GJ, Goloubeva O, Chumsri S, Nguyen N, Sukumar S, Brodie AM.
    Cancer Res; 2011 Mar 01; 71(5):1893-903. PubMed ID: 21245100
    [Abstract] [Full Text] [Related]

  • 2. Aromatase inhibitors and xenograft studies.
    Chumsri S, Sabnis GJ, Howes T, Brodie AM.
    Steroids; 2011 Jul 01; 76(8):730-5. PubMed ID: 21420993
    [Abstract] [Full Text] [Related]

  • 3. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.
    Sabnis GJ, Goloubeva OG, Kazi AA, Shah P, Brodie AH.
    Mol Cancer Ther; 2013 Dec 01; 12(12):2804-16. PubMed ID: 24092810
    [Abstract] [Full Text] [Related]

  • 4. Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
    Schech AJ, Shah P, Yu S, Sabnis GJ, Goloubeva O, Rosenblatt P, Kazi A, Chumsri S, Brodie A.
    Breast Cancer Res Treat; 2015 Aug 01; 152(3):499-508. PubMed ID: 26133921
    [Abstract] [Full Text] [Related]

  • 5. Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice.
    Hirakawa H, Yokoyama Y, Yoshida H, Mizunuma H.
    J Ovarian Res; 2014 Jan 10; 7():4. PubMed ID: 24410765
    [Abstract] [Full Text] [Related]

  • 6. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
    Jelovac D, Sabnis G, Long BJ, Macedo L, Goloubeva OG, Brodie AM.
    Cancer Res; 2005 Jun 15; 65(12):5380-9. PubMed ID: 15958587
    [Abstract] [Full Text] [Related]

  • 7. Inhibitory effects of calcitriol on the growth of MCF-7 breast cancer xenografts in nude mice: selective modulation of aromatase expression in vivo.
    Swami S, Krishnan AV, Wang JY, Jensen K, Peng L, Albertelli MA, Feldman D.
    Horm Cancer; 2011 Jun 15; 2(3):190-202. PubMed ID: 21686077
    [Abstract] [Full Text] [Related]

  • 8. Extending aromatase inhibitor sensitivity in hormone resistant breast cancer.
    Brodie AM, Chumsri S, Sukumar S, Sabnis GJ.
    Horm Mol Biol Clin Investig; 2011 Mar 01; 5(2):97-103. PubMed ID: 25961245
    [Abstract] [Full Text] [Related]

  • 9. Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo.
    Banerjee S, A'Hern R, Detre S, Littlewood-Evans AJ, Evans DB, Dowsett M, Martin LA.
    Clin Cancer Res; 2010 Aug 15; 16(16):4178-87. PubMed ID: 20682704
    [Abstract] [Full Text] [Related]

  • 10. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.
    Andreucci E, Francica P, Fearns A, Martin LA, Chiarugi P, Isacke CM, Morandi A.
    Oncotarget; 2016 Dec 06; 7(49):80543-80553. PubMed ID: 27602955
    [Abstract] [Full Text] [Related]

  • 11. Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment.
    Sabnis G, Goloubeva O, Gilani R, Macedo L, Brodie A.
    Mol Cancer Ther; 2010 Jan 06; 9(1):46-56. PubMed ID: 20053764
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
    Sabnis G, Brodie A.
    Clin Breast Cancer; 2010 Feb 06; 10(1):E6-E15. PubMed ID: 20133251
    [Abstract] [Full Text] [Related]

  • 16. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
    Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AM.
    Cancer Res; 2005 Jun 15; 65(12):5439-44. PubMed ID: 15958593
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
    Lisztwan J, Pornon A, Chen B, Chen S, Evans DB.
    Breast Cancer Res; 2008 Jun 15; 10(4):R56. PubMed ID: 18611244
    [Abstract] [Full Text] [Related]

  • 19. Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.
    Dabydeen SA, Kang K, Díaz-Cruz ES, Alamri A, Axelrod ML, Bouker KB, Al-Kharboosh R, Clarke R, Hennighausen L, Furth PA.
    Carcinogenesis; 2015 Jan 15; 36(1):122-32. PubMed ID: 25421723
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.